ACP
REGN icon

Aveo Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Aveo Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-436
Closed -$315K – 365
2022
Q4 		$315K Buy
436
+73
+20% +$53.9K 0.05% 257
2022
Q3 		$250K Buy
+363
New +$228K 0.04% 238

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Aveo Capital Partners's REGN Position: Q1 2023 in Review

Aveo Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 436 shares — an estimated $315K sold.

Aveo Capital Partners first reported a position in REGN in Q3 2022 and held it in 2 quarters. The position peaked at $315K in Q4 2022. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

  • Aveo Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Aveo Capital Partners sold 436 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $315K.
  • Aveo Capital Partners first reported a position in Regeneron Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Aveo Capital Partners's Regeneron Pharmaceuticals position peaked at $315K in Q4 2022.
  • 1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Aveo Capital Partners's 13F filing for Q1 2023, filed 3 May 2023.